P

ProKidney Corp. Tech Stack

Autologous cellular therapy for chronic kidney disease in Phase 2/3 trials

Biotechnology Research Winston-Salem, North Carolina 51–200 employees Public Company

ProKidney develops rilparencel, a first-in-class autologous cellular therapy for diabetic kidney disease, currently in Phase 2 and Phase 3 clinical evaluation with FDA RMAT designation. The hiring mix—dominated by manufacturing (8 roles) and quality (3 roles) with accelerating velocity—reflects a company transitioning from research to GMP-scale manufacturing and compliance readiness, a phase typically marked by operational friction around process deviation, inspection prep, and digital manufacturing integration.

Tech Stack 13 technologies

Core StackPython Tableau Excel Visio RNA-seq ATAC-seq 10x Genomics RT-qPCR LIMS Word PowerPoint R Spotfire

What ProKidney Corp. Is Building

◆Challenges

Ensuring cgmp compliance
Inspection readiness
Reducing deviations
Cost reduction in manufacturing
Compliance readiness
Process deviation recurrence
Quality compliance risk
Training compliance gaps
Digital transformation in manufacturing
Timely completion of contracts

▲Active Projects

Special projects on analytical methods and instrumentation problems related to execution of assays
Capa remediation
Data repository development
Process improvement strategy implementation
Digital transformation of manufacturing operations
Change management for new process adoption
Change control management
Root cause analysis
Internal audit support
Cmc gmp document development

Hiring Activity

Accelerating20 roles · 10 in 30d

Department

Manufacturing

8

Quality

3

Engineering

2

Ops

2

Research

2

Data

1

Legal

1

Regulatory

1

Seniority

Senior

8

Mid

7

Director

2

Manager

2

Principal

1

Notable leadership hires: Director, Quality Operations, Scientific Director

Company intelligence

Find more companies like ProKidney Corp. by tech stack, pain points and active projects

Get started free

About ProKidney Corp.

ProKidney is a clinical-stage biotherapeutics company focused on treating chronic kidney disease through cellular therapy innovations. The company's lead candidate, rilparencel (REACT®), is designed to preserve kidney function in diabetic patients at high risk of progression to kidney failure. Founded in 2015 after a decade of prior research, ProKidney is headquartered in Winston-Salem, North Carolina, and operates as a public company. Current operational focus spans clinical trial execution, manufacturing scale-up, and regulatory compliance preparation.

HeadquartersWinston-Salem, North Carolina

Company Size51–200 employees

Hiring MarketsUnited States

Frequently Asked Questions

What is ProKidney's lead product candidate?

Rilparencel (REACT®), a first-in-class autologous cellular therapy in Phase 2 and Phase 3 studies for diabetic kidney disease. It has FDA Regenerative Medicine Advanced Therapy (RMAT) designation.